| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 51.18% | Morgan Stanley | $0.88 → $0.96 | Maintains | Equal-Weight |
| 10/30/2023 | 38.58% | Morgan Stanley | $1.44 → $0.88 | Maintains | Equal-Weight |
| 09/27/2023 | 136.22% | Roth MKM | → $1.5 | Reiterates | Buy → Buy |
| 08/09/2023 | 126.77% | Morgan Stanley | $1.4 → $1.44 | Maintains | Equal-Weight |
| 08/09/2023 | 214.96% | Piper Sandler | → $2 | Reiterates | Neutral → Neutral |
| 05/11/2023 | 844.88% | Oppenheimer | → $6 | Reiterates | Outperform → Outperform |
| 05/11/2023 | 120.47% | Morgan Stanley | $2.5 → $1.4 | Maintains | Equal-Weight |
| 05/11/2023 | 214.96% | Piper Sandler | → $2 | Reiterates | → Neutral |
| 03/28/2023 | 214.96% | Piper Sandler | $2.25 → $2 | Maintains | Neutral |
| 03/24/2023 | 214.96% | Baird | $3 → $2 | Maintains | Outperform |
| 11/09/2022 | 293.7% | Morgan Stanley | $5 → $2.5 | Maintains | Equal-Weight |
| 11/09/2022 | 254.33% | Piper Sandler | $4.5 → $2.25 | Maintains | Neutral |
| 11/02/2022 | 372.44% | WestPark Capital | → $3 | Initiates Coverage On | → Hold |
| 08/04/2022 | 608.66% | Piper Sandler | $3 → $4.5 | Maintains | Neutral |
| 07/18/2022 | 372.44% | Piper Sandler | $5 → $3 | Downgrades | Overweight → Neutral |
| 05/05/2022 | 687.4% | Piper Sandler | $6 → $5 | Maintains | Overweight |
| 04/14/2022 | 844.88% | Credit Suisse | → $6 | Initiates Coverage On | → Outperform |
| 02/24/2022 | 687.4% | Morgan Stanley | $11 → $5 | Maintains | Equal-Weight |
| 02/24/2022 | 844.88% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 01/13/2022 | 1474.8% | Piper Sandler | $12 → $10 | Maintains | Overweight |
| 07/19/2021 | 1632.28% | Morgan Stanley | → $11 | Initiates Coverage On | → Equal-Weight |
| 07/07/2021 | 2734.65% | New Street Research | → $18 | Initiates Coverage On | → Buy |
| 05/14/2021 | 2419.69% | Piper Sandler | $22 → $16 | Maintains | Overweight |
| 04/01/2021 | 3049.61% | Baird | → $20 | Initiates Coverage On | → Outperform |
| 03/19/2021 | 3049.61% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 03/18/2021 | 3049.61% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 03/18/2021 | 3364.57% | Piper Sandler | → $22 | Initiates Coverage On | → Overweight |
| 03/17/2021 | 3837.01% | Craig-Hallum | → $25 | Initiates Coverage On | → Buy |
| 03/17/2021 | 4624.41% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
What is the target price for Aeva Technologies (AEVA)?
The latest price target for Aeva Technologies (NYSE: AEVA) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $0.96 expecting AEVA to rise to within 12 months (a possible 51.18% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aeva Technologies (AEVA)?
The latest analyst rating for Aeva Technologies (NYSE: AEVA) was provided by Morgan Stanley, and Aeva Technologies maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Aeva Technologies (AEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aeva Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aeva Technologies was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Aeva Technologies (AEVA) correct?
While ratings are subjective and will change, the latest Aeva Technologies (AEVA) rating was a maintained with a price target of $0.88 to $0.96. The current price Aeva Technologies (AEVA) is trading at is $0.64, which is out of the analyst's predicted range.